Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas
Public ClinicalTrials.gov record NCT02213133. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-Label Study of the Safety and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck, Lung, or Esophagus
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Open-label, multi-center, single-arm, Phase 2 study of oral selinexor in patients with SCC of the head and neck (HN-SCC; Cohort 1), lung (L-SCC; Cohort 2), or esophagus (E-SCC; Cohort 3) who have relapsed or have metastasis following chemotherapy.
Study identification
- NCT ID
- NCT02213133
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 45 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 22, 2014 (Actual)
- Primary completion
- Dec 10, 2015 (Actual)
- Completion
- Dec 10, 2015 (Actual)
- Last update posted
- Jan 26, 2023
2014 – 2015
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | — |
| Northwestern University | Evanston | Illinois | 60208 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| Dana-Farber Cancer Institute / Harvard University | Boston | Massachusetts | 02215 | — |
| Metrowest Medical Center | Framingham | Massachusetts | 01702 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Washington University School of Medicine / Washington University in St. Louis | St Louis | Missouri | 63130 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029-6574 | — |
| Herbert Irving Comprehensive Cancer Center / Columbia University | New York | New York | 10032 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Sarah Cannon Research Institute - Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Vanderbilt-Ingram Cancer Center / Vanderbilt University | Nashville | Tennessee | 37232 | — |
| Mary Crowley Cancer Research Center / Texas Oncology | Dallas | Texas | 75201 | — |
| University of Washington | Seattle | Washington | 63110 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02213133, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 26, 2023 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02213133 live on ClinicalTrials.gov.